Around 70% of all breast tumors are of the luminal subtype, in which estrogen receptor‐alpha (ERα) is the main driver of cell proliferation, and consequently the prime drug target in treatment (Beelen et al., 2012; Droog et al., 2013). The gene discussed is ESR1; the disease is breast neoplasm.